Kevin D. Bunker, Chief Scientific Officer at Zentalis Pharmaceuticals, Inc. (ZNTL), sold 11,153 shares at $19.43 ($217K) on 2023-10-04, disclosed to the SEC on 2023-10-06.
Scheduled sale ($217k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.43 | 5,085 | $99K | 45.5% |
| 2 | $19.43 | 5,085 | $99K | 45.5% |
| 3 | $19.91 | 983 | $20K | 9.0% |
| Total | $19.47 avg | 11,153 | $217K | 100% |
| Filing → |
| ZNTL | SELL | 2022-08-12 | $150K | — | Filing → |
| ZNTL | SELL | 2022-07-20 | $150K | — | Filing → |
| ZNTL | SELL | 2022-07-14 | $300K | — | Filing → |